Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr

Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin

Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL

Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia

HCG Manavata Cancer Centre completes world-first in robotic-assisted nipple sparing mastectomy

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept

Supriya Lifescience names Dr. Saloni Wagh as MD

Shivani Satish Wagh takes on the role of Joint Managing Director

Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr

Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore

Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024

Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid

Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones

Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY